March 14, 2023 7:25am

Share pricing opportunities appearing after selling off in cell and gene therapy equities for investors looking to scoop up shares; however, will electronic trading/algorithms now profit?

Earnings: Agenus (AGEN) and AxoGen (AXGN)

Pre-open Indications: 5 Sell into Strength, 1 Positive and 4 Negative Indication

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

The 8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on will happen behind the headlines today, not tomorrow or yesterday …

 

Dow futures are UP +0.44% or (+141 points), S&P futures are UP +0.50% or (+19 point) and NASDAQ futures are UP +0.45% or (+54 points) early in the pre-open – so far

U.S. stock futures are rising on Tuesday,

European markets were cautiously higher,

Asia-Pacific markets tumbled in a volatile session.

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes inched up Monday as failed Silicon Valley Bank was back-stopped by FDIC, Fed and Treasury to make withdrawals available for depositors.

Monday, the Dow closed DOWN -90.50 points (-0.28%); the S&P closed DOWN -5.83 points (-0.15%) while the Nasdaq closed UP +49.96 points (+0.45%.

Today’s inflation report could be another headache for the Fed and … is the last significant report on U.S. consumer prices before the Federal Reserve meets on March 21-22 to make its next interest-rate decision. <Barron’s>

Economic Data Docket: February consumer price index is expected to show a rise of 0.4% last month, according to consensus estimates from Dow Jones; that’s down from a 0.5% increase the prior month.

Tuesday’s consumer price index report is the last major inflation data release ahead of the Fed’s next meeting, ending March 22. February retail sales and the producer price index are also on deck.

 

Monday’s (3/13) … RegMed Investors’ (RMi) closing bell: “sector equities turn up from being oversold clouded by SVB’s decline. Along came the cell/gene therapy sector climbing back because of SVB worry and share pricing fear. in the UK, HSBC step-in and bought the U.K. subsidiary of Silicon Valley Bank.” … https://www.regmedinvestors.com/articles/12869

 

RegMed Investors (RMi) Research Note: Upcoming Q4 earnings reporting dates … https://www.regmedinvestors.com/articles/12830

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … “The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth” … https://www.regmedinvestors.com/articles/12843 --- 21 of 35 (my coverage group)

 

Ebb and flow:

Q1/23 –

March – 2 positive and 7 negative close

·         February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

·         January – 2 holidays, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Sell into Strength indication:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

·         Beam Therapeutics (BEAM) closed up +$1.62 with a positive +1.24 or +3.67% aftermarket indication.

·         BioLife Solutions (BLFS) closed up +$1.27 with a positive +$1.03 or +4.96% aftermarket indication.

·         Intellia Therapeutics (NTLA) closed up +$2.49 with a positive +$0,73 or +1.91% pre-open indication.

·         uniQure NV (QURE) closed up +$0.40 with a positive +$0.92 or +4.70% aftermarket indication.

·         Vericel (VCEL) closed up +$0.18 with a positive +$1.47 or +4.97% aftermarket indication.

Negative indications:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

·         AxoGen (AXGN) closed down -$0.05 with a negative -$0.13 or -1.73% aftermarket indication and earnings’ release.

·         CRISPR Therapeutics (CRSP) closed up +$2.50 with a negative -$0.72 or -1.157% aftermarket indication.

·         Sage Therapeutics (SAGE) closed up +$3.80 with a negative -$0.36 or -0.83% aftermarket indication

·         Ultragenyx Pharmaceuticals (RARE) closed up +$2.12 with a negative -$0.88 or -2.15% aftermarket indication

Positive Indications:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

·         Caribou Biosciences (CRBU) closed up +$0.15 with a positive +$0.10 or +1.88% aftermarket indication,

 

The BOTTOM LINE: I try to keep it simple and short!

Monday’s share pricing finished up as volatile trading gripped the sector after federal banking regulators took aggressive actions to stem the fallout of Silicon Valley Bank's failure.

Reiterating: “If economic data releases were hard enough to hurdle i.e.; share pricing deep dives in the new month’s eight (8) sessions contributes, following the collapse of Silicon Valley Bank (SVB) that effected not just investors and companies but, employee’s payrolls contributing to the last week’s conflagration.”

Economic <Consumer Price Index (CPI) – today and Wednesday’s retail sales> releases will also dominate the conversation this week as two data points as the Fed’s next meeting rapidly approaches.

Also, the rush of Q4 and FY22 earnings to release is STILL on … I do NOT believe there are not a lot of cell/gene therapy companies in position yet – UNTIL earnings (Q4 and FY22) are reported – any breakout is a false hope with the inevitable downside re-occurring.

21 of my 35 covered have reported – 2 today.

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product.

And I can always be WRONG but, mostly EARLY!

Upcoming Q4 earnings reporting will present challenges to share pricing.

·         BioLife Solutions (BLFS) 3/16 – Thursday

·         There are more coming – waiting for announcements

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.